1-tert.-Butyl-3-tert.-butylamino-azetidin | 26146-50-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丙烷
• 英文名称: 1-tert.-Butyl-3-tert.-butylamino-azetidin
• 英文别名: tert-butyl-(1-tert-butyl-azetidin-3-yl)-amine；N,1-ditert-butylazetidin-3-amine
• CAS: 26146-50-9
• 化学式: C₁₁H₂₄N₂
• 分子量: 184.325
• InChiKey: FKFNDHOCTYPBAA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS
  申请人：Hubschwerlen Christian

  公开号：US20120322766A1

  公开（公告）日：2012-12-20

  The present invention relates to the use of compounds, in which the pharmacophores of quinolone and oxazolidinone are chemically linked together through a linker that is stable under physiological conditions, for the treatment of anthrax and other infections.

  本发明涉及使用化合物，其中喹诺酮和噁唑烷酮的药效团经过稳定在生理条件下的连接剂化学连接在一起，用于治疗炭疽和其他感染病。
• Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections
  申请人：Hubschwerlen Christian

  公开号：US20070155714A1

  公开（公告）日：2007-07-05

  The present invention relates to the use of compounds, in which the pharmacophores of quinolone and oxazolidinone are chemically linked together through a linker that is stable under physiological conditions, for the treatment of anthrax and other infections.

  本发明涉及使用化合物，其中喹诺酮和噁唑烷酮的药效团通过在生理条件下稳定的链接剂进行化学连接，用于治疗炭疽病和其他感染。
• DUAL ACTION ANTIBIOTICS
  申请人：Hubschwerlen Christian

  公开号：US20110059946A1

  公开（公告）日：2011-03-10

  The present invention relates to compounds of the Formula (I) that are useful antimicrobial agents and effective against a variety of multi-drug resistant bacteria:

  本发明涉及式（I）的化合物，它们是有用的抗微生物药物，并且对各种多药耐药细菌有效。
• Heterocyclic degronimers for target protein degradation
  申请人：C4 Therapeutics, Inc.

  公开号：US10646575B2

  公开（公告）日：2020-05-12

  This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) (“Degrons”), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.

  本发明提供了能与 E3 泛素连接酶（通常是通过脑龙）（"Degrons"）结合的杂环化合物，这些杂环化合物可用于治疗目的或与选定靶蛋白的靶向配体相连接，并提供了其使用方法和组合物及其制备方法。
• Spirocyclic degronimers for target protein degradation
  申请人：C4 Therapeutics, Inc.

  公开号：US10660968B2

  公开（公告）日：2020-05-26

  This invention provides compounds that have spirocyclic E3 Ubiquitin Ligase targeting moieties (Degrons), which can be used as is or linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.

  本发明提供了具有螺环 E3 泛素连接酶靶向基团（Degrons）的化合物，这些化合物可单独使用，也可与用于体内降解的蛋白质的靶向配体连接，本发明还提供了其使用方法和组合物及其制备方法。